Supporting our mechanistic findings, Kaplan–Meier analyses of the TCGA data revealed that high EZH2 and low HNF1B expression were associated with a substantial increase of the relapse frequency while high HNF1B and low EZH2 showed the best prognoses (Fig. 2f), pinpointing the clinical relevance of our findings of EZH2 acts as an oncogenic player at least partially through suppression of HNF1B in prostate cancer. The gene discussed is EZH2; the disease is Familial prostate cancer.